Aims and scope
Advances in Rheumatology is an international, open access journal publishing pre-clinical, translational and clinical studies on all aspects of paediatric and adult rheumatic diseases, including degenerative, inflammatory and autoimmune conditions. The journal is the official publication of the Brazilian Society of Rheumatology and welcomes original research (including systematic reviews and meta-analyses), literature reviews, guidelines and letters arising from published material.
All articles published by Advances in Rheumatology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Advances in Rheumatology you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
The publication costs for Advances in Rheumatology are covered by the Brazilian Society of Rheumatology so authors do not need to pay an article-processing charge.
All articles published in Advances in Rheumatology are included in:
- Emerging Sources Citation Index (ESCI)
- Index Copernicus
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in Advances in Rheumatology will be available in their databases when appropriate.
Advances in Rheumatology operates a double-blind peer-review system, where the reviewers do not know the names or affiliations of the authors and the reviewer reports provided to the authors are anonymous.
The benefit of double-blind peer review is that it allows reviewers to judge the manuscript based on content alone, and they are not unconsciously biased by knowledge of who the authors are.
Submitted manuscripts will initially be screened by the Editor-in-Chief, with manuscripts deemed of suitable quality and interest assigned to the relevant Associate Editor. Manuscripts will generally be reviewed by two or more experts, who will be asked to assess the manuscript and provide constructive comments for improvement.
All manuscripts submitted to Advances in Rheumatology should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Advances in Rheumatology
Articles in Advances in Rheumatology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Adv Rheumatol [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Adv Rheumatol 2009, 1:115.
1:115 refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Advances in Rheumatology
Advances in Rheumatology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Advances in Rheumatology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Advances in Rheumatology gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Advances in Rheumatology are included in article alerts and regular email updates. Some may be highlighted on Advances in Rheumatology’s pages and on the BioMed Central homepage.
In addition, articles published in Advances in Rheumatology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Advances in Rheumatology. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Advances in Rheumatology you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
Official journal of
Brazilian Society of Rheumatology
Annual Journal Metrics
99 days to first decision for reviewed manuscripts only
70 days to first decision for all manuscripts
96 days from submission to acceptance
29 days from acceptance to publication
196 Altmetric mentions